Genetic polymorphism of NAT2 metabolizing enzymes on phenytoin pharmacokinetics in Indian epileptic patients developing toxicity
- PMID:22268821
- PMCID: PMC6493548
- DOI: 10.1111/j.1755-5949.2011.00291.x
Genetic polymorphism of NAT2 metabolizing enzymes on phenytoin pharmacokinetics in Indian epileptic patients developing toxicity
Abstract
Objective: To investigate the effects of NAT2 metabolizing enzymes on the pharmacokinetics of antiepileptic drug phenytoin in the epileptic patients showing toxicity.
Methods: Fifty epileptic individuals who had developed toxicity to phenytoin and 50 control epileptic subjects who had not developed toxicity to phenytoin were genotyped for NAT2 (NAT2*5A, NAT2*5C, NAT2*7, NAT2*6) polymorphisms by polymerase chain reaction-restriction fragment length polymorphisms (PCR-RFLP method). Phenytoin plasma levels were analyzed by reversed phase HPLC method and pharmacokinetic parameters such as area under the concentration curve (AUC), maximum concentration (C(max)), time to C(max) (t(max)) and half-life (t(1/2)) were estimated by noncompartmental analysis using PK Solutions® software.
Results: The NAT2 polymorphism was seen to be in Hardy-Weinberg equilibrium and showed significant genotypic as well as allelic association with phenytoin toxicity for NAT2*5A (481C>T) and NAT2*5C (803A>G). Pharmacokinetic parameters for phenytoin in toxicity group of poor metabolizers showed a longer elimination half-life of a drug (t(1/2) = 35.3 h) and less clearance rate (CL = 468 mL/h) compared to intermediate metabolizers (t(1/2) = 33.2 h, CL = 674 mL/h) and extensive metabolizer (t(1/2) = 20.7 h, CL = 977 mL/h) in NAT2*5A polymorphism.
Conclusion: Our findings suggest that the NAT2*5A genetic polymorphisms plays a significant role in the steady-state concentrations of phenytoin and thereby have impact on toxicity in epileptic patients.
© 2012 Blackwell Publishing Ltd.
Conflict of interest statement
The authors has no conflict of interest.
Figures
Comment in
- Functional genetic polymorphisms from phase-II drug metabolizing enzymes.Grover S, Kukreti R.Grover S, et al.CNS Neurosci Ther. 2012 Aug;18(8):705-6. doi: 10.1111/j.1755-5949.2012.00343.x. Epub 2012 May 22.CNS Neurosci Ther. 2012.PMID:22613669Free PMC article.No abstract available.
Similar articles
- Functional genetic polymorphisms from phase-II drug metabolizing enzymes.Grover S, Kukreti R.Grover S, et al.CNS Neurosci Ther. 2012 Aug;18(8):705-6. doi: 10.1111/j.1755-5949.2012.00343.x. Epub 2012 May 22.CNS Neurosci Ther. 2012.PMID:22613669Free PMC article.No abstract available.
- The effect of uridine diphosphate glucuronosyltransferase (UGT)1A6 genetic polymorphism on valproic acid pharmacokinetics in Indian patients with epilepsy: a pharmacogenetic approach.Munisamy M, Tripathi M, Behari M, Raghavan S, Jain DC, Ramanujam B, Arumugam K, Rajakannan T, Mallayasamy SR, Subbiah V.Munisamy M, et al.Mol Diagn Ther. 2013 Oct;17(5):319-26. doi: 10.1007/s40291-013-0041-8.Mol Diagn Ther. 2013.PMID:23749495
- Association ofNAT-2 gene polymorphisms toward lung cancer susceptibility and prognosis in North Indian patients treated with platinum-based chemotherapy.Walia HK, Singh N, Sharma S.Walia HK, et al.Pharmacogenomics. 2022 Jan;23(2):97-118. doi: 10.2217/pgs-2021-0080. Epub 2021 Dec 16.Pharmacogenomics. 2022.PMID:34911343
- Molecular mechanisms of genetic polymorphisms of drug metabolism.Meyer UA, Zanger UM.Meyer UA, et al.Annu Rev Pharmacol Toxicol. 1997;37:269-96. doi: 10.1146/annurev.pharmtox.37.1.269.Annu Rev Pharmacol Toxicol. 1997.PMID:9131254Review.
- Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity.Walker K, Ginsberg G, Hattis D, Johns DO, Guyton KZ, Sonawane B.Walker K, et al.J Toxicol Environ Health B Crit Rev. 2009;12(5-6):440-72. doi: 10.1080/10937400903158383.J Toxicol Environ Health B Crit Rev. 2009.PMID:20183529Review.
Cited by
- NAT2 gene polymorphism: covert drug interaction causing phenytoin toxicity.Adithan C, Subathra A.Adithan C, et al.Indian J Med Res. 2016 May;143(5):542-4. doi: 10.4103/0971-5916.187101.Indian J Med Res. 2016.PMID:27487996Free PMC article.No abstract available.
- Functional genetic polymorphisms from phase-II drug metabolizing enzymes.Grover S, Kukreti R.Grover S, et al.CNS Neurosci Ther. 2012 Aug;18(8):705-6. doi: 10.1111/j.1755-5949.2012.00343.x. Epub 2012 May 22.CNS Neurosci Ther. 2012.PMID:22613669Free PMC article.No abstract available.
- N-acetyltransferase 2 (NAT2) gene polymorphism as a predisposing factor for phenytoin intoxication in tuberculous meningitis or tuberculoma patients having seizures - A pilot study.Adole PS, Kharbanda PS, Sharma S.Adole PS, et al.Indian J Med Res. 2016 May;143(5):581-90. doi: 10.4103/0971-5916.187106.Indian J Med Res. 2016.PMID:27488001Free PMC article.
References
- Shorvon SD. Handbook of the treatment of epilepsy. Oxford : Blackwell Science, 2000;252 pp. ISBN 0‐632‐04849‐2.
- Shridharan R, Murthy BN. Prevalence and pattern of epilepsy in India. Epilepsia 1999;40:631–636. - PubMed
- Najm IM, Moddel G, Janigro D. Mechanisms of epileptogenesis and experimental models of seizures In: Wyllie E, editor. The treatment of epilepsy, 4th ed Philadelphia : Lippincott Williams & Wilkins, 2006;91–102.
- Odani A, Hashimoto Y, Otsiki Y, Uuai Y, Hattori H, Furusho K. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther 1997;62:287–292. - PubMed
- Evans DAP. N‐Acetyltransferase. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York : Pergamon Press, 1992;95–178.